Every investor in SOPHiA GENETICS SA (Nasdaq: SOPH) You need to be aware of the strongest stakeholder groups. With a share of 47%, individual investors own the maximum shares in the company. That is, the group will benefit the most if the stock goes up (or loses the most in the event of a downturn).
While institutions with 32% came under pressure after the market capitalization plunged to $173 million last week, retail investors suffered the most.
Let’s dive into each type of SOPHiA GENETICS owner, starting with the chart below.
If you are not interested in researching the SOPH ownership structure, we have a file Free list of Interesting investment ideas To inspire your next investment!
What does corporate ownership tell us about SOPHiA GENETICS?
Many institutions benchmark their performance against an indicator that approximates the local market. So they usually pay more attention to the companies listed in the major indices.
As you can see, institutional investors own a fair stake in SOPHiA GENETICS. This means that analysts working at those institutions have looked at the stock and liked it. But like everyone else, they can be wrong. It is not uncommon to see a significant drop in the stock price if two large institutional investors attempt to sell a stock at the same time. It is therefore worth checking out the SOPHiA GENETICS past earnings path (below). Of course, keep in mind that there are other factors to consider as well.
We note that hedge funds do not have a beneficial investment in SOPHiA GENETICS. Alychlo NV is currently the largest shareholder, with 11% of the shares outstanding. Meanwhile, the second and third largest shareholders own 11% and 5.2% of the shares outstanding, respectively. Additionally, we found that Jorgi Camblong, CEO has 3.4% of the stock assigned to their name.
Looking at the record of the shareholders, we can see that 50% of the ownership is held by the 14 largest shareholders, which means that not a single shareholder has a majority stake in the ownership.
While it makes sense to study a company’s corporate ownership data, it also makes sense to study analyst sentiment to see which direction the wind is blowing. Quite a few analysts cover stocks, so you can look at growth forecasts quite easily.
Insider Ownership of Sophia Genetics
The definition of company insiders can be subjective and does not vary across jurisdictions. Our data reflects individual insiders, capturing directors at the very least. Management ultimately responds to the board of directors. However, it is not uncommon for directors to be members of the executive board, especially if they are a founder or CEO.
In general, I consider internal ownership a good thing. However, in some cases, it is difficult for other shareholders to hold the board of directors accountable for decisions.
Our most recent data indicates that insiders own some shares in SOPHiA GENETICS SA. In their own name, the insiders own $8.5 million worth of shares in the $173 million company. Some would say that this shows a alignment of interests between the shareholders and the board of directors, although we generally prefer to see larger internal holdings. But it might be worth checking out If these insiders sell.
With 47% ownership, the general public, which consists mostly of individual investors, has some degree of influence over SOPHiA GENETICS. While this group cannot necessarily make decisions, it certainly can have a real impact on how the company is run.
private equity ownership
Private equity firms own 16% of Sophia Genetics’ shares. This indicates that they can be influential in major policy decisions. Some may like this, because private equity is sometimes activists holding management accountable. But other times, private equity runs out, leading the company to go public.
It is always worth considering the different groups that own shares in the company. But to better understand Sophia’s genes, we need to take into account many other factors. Take, for example, the specter of perpetual investment risk. We have identified 3 warning signs With SOPHiA GENETICS (at least one related) Understanding it should be part of your investing process.
But in the end It’s the future, and not the past, will determine how well the owners of that business perform. So we think it’s a good idea to take a look at This free report shows whether analysts are expecting a brighter future.
Note: The numbers in this article are calculated using data from the last twelve months, which refers to the 12-month period ending on the last date of the month in which the financial statement was dated. This may not be consistent with the annual report figures for the full year.
Do you have feedback on this article? Worried about the content? keep in touch with us directly. Alternatively, email the editorial team (at) simplewallst.com.
This article by Simply Wall St is general in nature. We provide comments based only on historical data and analyst expectations using an unbiased methodology and our articles are not intended as financial advice. It does not constitute a recommendation to buy or sell any stock, nor does it take into account your objectives or financial situation. We aim to provide you with focused, long-term analysis driven by essential data. Note that our analysis may not include the company’s most recent price-sensitive ads or quality materials. Wall Street simply has no position in any of the stocks mentioned.
Evaluation is complex, but we help simplify it.
Find out if SOPHiA GENETICS has likely been overtaken or undervalued by checking out our comprehensive analysis, which includes Fair value estimates, risks, warnings, dividends, insider transactions and financial soundness.